

## ESPS PEER REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**ESPS manuscript NO:** 12864

**Title:** Survival in unresectable sinonasal undifferentiated carcinoma treated with concurrent intra-arterial cisplatin and radiation

**Reviewer code:** 02458758

**Science editor:** Fang-Fang Ji

**Date sent for review:** 2014-07-28 19:41

**Date reviewed:** 2014-08-16 11:07

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

## COMMENTS TO AUTHORS

The manuscript "Survival in unresectable sinonasal undifferentiated carcinoma treated with concurrent intra-arterial cisplatin and radiation " is describing the the successful use of RADPLAT to treat a patient with an unresectable T4N0 sinonsal undifferentiated carcinoma (SNUC). These data are thorough and convincing, but lack critical controls, it can't exclude the factors of non- RADPLAT. This control is critical, if , The author can provide the parallel-group, The conclusion will be more credible.